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High-fructose diet is known to produce cardiovascular and metabolic pathologies. The objective was to determine whether the
timing of high fructose (10% liquid solution) intake aﬀect the metabolic and cardiovascular outcomes. Male C57BL mice with
radiotelemetric probes were divided into four groups: (1) 24 h water (control); (2) 24 h fructose (F24); (3) 12 h fructose during
the light phase (F12L); (4) 12 h fructose during the dark phase (F12D). All fructose groups had higher fluid intake. Body weight
was increased in mice on restricted access with no diﬀerence in total caloric intake. Fasting glycemia was higher in groups with
restricted access. F24 mice showed a fructose-induced blood pressure increase during the dark period. Blood pressure circadian
rhythms were absent in F12L mice. Results suggest that the timing of fructose intake is an important variable in the etiology of
cardiovascular and metabolic pathologies produced by high fructose consumption.

1. Introduction
Given the substantial levels of fructose consumption in our
everyday diet, it is important to delineate its consequences
[1, 2]. There is compelling evidence that increased fructose
intake has metabolic and cardiovascular eﬀects in both human and animals [3–8]. Our group showed that a highfructose diet in mice produced glucose intolerance and increased blood pressure [4, 6]. Evidence also showed that sympathetic activation occurred rapidly before fructose induction of metabolic dysfunction [9]. A clinical study showed
that ingestion of water containing 60 g of fructose acutely
elevates blood pressure in healthy human subjects [3].
In addition to the global detrimental eﬀects of high
fructose intake, the timing of consumption might also play
a causative role in the metabolic and cardiovascular pathologies. There are many examples of work and lifestyle patterns
that require alternative intake cycles. This is seen in public
service work: police and fire protection, transportation, and
utilities, all of which rely on 24 hr around the clock attention.

Likewise, shift work as required in health care or manufacturing industries forces people to be active in the normal
sleeping phase of the light-dark (L/D) cycle. Obesity and
metabolic syndrome are often associated with the nocturnal
eating syndrome and shift work, demonstrating the connection between L/D cycle and metabolic pathologies [10–15].
Circadian misalignment has also been shown to produce
changes in glucose and insulin levels, as well as increases in
blood pressure, in both mice and humans [16–18]. Although
the mechanisms underlying these adverse cardiometabolic
changes remain unknown, it is possible that disturbances in
the sleep/wake and eating schedule, could, in turn, influence
appetite, food intake, and energy balance. This could have
important implications for the increased obesity, diabetes,
and cardiovascular disease in the shift work population [15].
In the context of the worldwide epidemic of obesity
and diabetes [19], the increase in sugar consumption in
our contemporary western diets [20], and the increase in
sedentary lifestyles [21], we conducted studies in mice to
evaluate the eﬀects of 24 h access to fructose as well as
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2. Methods
2.1. Animals, Surgery, and General Procedures. Eight-weekold male C57BL mice (∼25 gm, Harlan Inc, Indianapolis,
IN) were given water or fructose (10%) for 8 weeks. Groups
are (1) 24 h water (Control, n = 6); (2) 24 h fructose (F24,
n = 6); (3) 12 h fructose during the light phase (F12L,
n = 6); (4) 12 h fructose during the dark phase (F12D, n =
6). Animals were housed at 22◦ C under a 12/12 light/dark
cycle with ad libitum access to standard pellet chow and
water or fructose. Telemetric probes (model TA11PA-C10,
Data Sciences International, St. Paul, MN) were inserted
into the left common carotid artery at 6 weeks in mice
anesthetized with ketamine/xylazine (120 : 20 mg/kg, im).
The transmitter body was positioned subcutaneously on the
right flank [22, 23]. 24 h cardiovascular recordings, fluid, and
food consumption measurements were made at 8 wks. Body
weight was measured during the 2nd, 4th, and 8th weeks of
the experimental protocol.
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the influence of the timing of consumption (fructose access
provided only in the light or dark period). The parameters of
interest focused on cardiovascular and metabolic function:
24 hr L/D rhythm in BP, glucose tolerance, plasma insulin,
and the pattern and amount of fructose intake.
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Figure 1: Body weight gain as percentage increase from day 0 in
control and fructose-treated groups. ANOVA showed main eﬀect of
time (F (2.6156) = 8.97.23, P < 0.0012). ∗ P < 0.015 vs. 2 wks.
20

2.2. Glucose Tolerance Test (GTT). GTT was performed at the
beginning of the 8th week (last week) of the experimental
protocol. Mice were fasted, with animals receiving only water,
for 6 h. Blood samples were taken from a tail cut at 0, 15, 30,
60, and 90 min after i.p. glucose load (1.5 g/kg). Blood glucose was determined by Accu-Chek Advantage Blood Glucose Monitor (Roche Diagnostic Corporation, Indianapolis,
IN).
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2.3. Plasma Measurements. At the end of the 8th week of
treatment, mice were sacrificed by decapitation and trunk
blood was collected in ice-chilled heparinized tubes. Total
plasma cholesterol and triglycerides were determined by
colorimetric enzymatic assays (Thermo Fisher Scientific Inc.,
Waltham, MA). Plasma insulin levels were measured using a
multianalytic profiling beads assay (Linco Research Inc., St
Charles, MO).
2.4. Urinary Corticosterone Measurements. Spot urine samples (100∼100 uL) were collected during the last hour of
the light phase. Urinary corticosterone levels were measured
by radioimmunoassay (MP Biomedical, Orangeburg, NY,
USA). Urinary creatinine was measured by spectrophotometry (Microvue Creatinine Assay Kit, Quidel Corporation,
San Diego, USA). The corticosterone : creatinine ratio was
calculated for each urine specimen.
2.5. Statistics. Values were expressed as mean ± SEM. Data
were analyzed using ANOVA two-way or repeated measures
when applicable and followed by the Newman-Keuls test.
Diﬀerences were considered to be statistically significant at
P < 0.05.

Fructose

Figure 2: Daily total caloric intake and fructose percentage caloric
intake in control and fructose-treated groups.

3. Results
Baseline body weights (BWs) ranged from 26 to 28 g.
The percentage increase in BW over the 8 wk period was
significantly higher in the restricted access groups (Figure 1).
The F12L and F12D groups showed significant increases in
BW gain after 8 wks of treatment as compared to 2 wks (P <
0.05). Total caloric intake was not diﬀerent between groups
(Figure 2).
Fluid intake was measured during the light and dark
phases with significant eﬀects of diet, light/dark, and interaction between diet and light/dark (Figure 3). 24h fluid intake
was higher in F24 and F12D mice when compared to Control
group (P < 0.01). There were light/dark diﬀerences in intake
in Control, F24, and F12D groups. In the F12L group, there
was no diﬀerence in fluid intake between the light and
dark phases. In the restricted access groups, fluid intake was
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Table 1: Plasma insulin, triglycerides, and cholesterol and urinary
corticosterone.
Control
F24
F12 L
Insulin
0.6 ± 0.1 0.8 ± 0.1 0.5 ± 0.1
(ng/mL)
85 ± 1#
TGL (mg/dL) 104 ± 18 129 ± 13
Cholesterol
94 ± 11
94 ± 11
95 ± 13
(mg/dL)
Corti
0.24 ± 0.1 0.36 ± 0.1 0.36 ± 0.1
(mg/mmol/L)

F12 D
1.2 ± 0.3
89 ± 11#
81 ± 13
0.23 ± 0.1

Plasma insulin, triglycerides, and cholesterol levels were measured in
nonfasted mice at 8-9 wk. ANOVA showed a significant eﬀect of diet for
insulin (F (3.17) = 3.45, P < 0.05) and triglycerides (F (3.17) = 2.95, P <
0.05). # P < 0.01 vs. F24.

Table 2: Eﬀect of restricted fructose access on fluid intake.
Water
(Control)

F24

F12L

F12D

24 h volume
11.5 ± 0.7 20.2 ± 2.4∗ 11.5 ± 1.6 19.8 ± 1.5∗
(mL)
Light phase
30.4 ± 6.0 32.8 ± 3.9 44.0 ± 1.8∗ 25.4 ± 5.6
(%)
Dark phase
69.6 ± 6.0# 67.2 ± 3.9# 56.0 ± 1.8 74.6 ± 5.6#
(%)
ANOVA showed a significant eﬀect of diet for 24 h volume intake [F (3.21) =
8.9, P < 0.001]. ANOVA showed main eﬀect of light/dark [F (1.42) = 100.6,
P < 0.00001] and interaction between light/dark and diet [F (3.42) = 5.6,
P < 0.003]. ∗ P < 0.01 vs. Control. # P < 0.01 vs. light.

greatest during the fructose consuming period, light for F12L
and dark for F12D (P < 0.01 vs. Control). With regard to the
percentage fluid intake during light and dark phases, mice
consuming fructose during the dark period drank a greater
percentage of fluid, 67–74%, during this phase (Table 2).
Mice given fructose during the light period drank almost
equal amounts during the light and dark (44 and 56% resp.).
Fasting glucose was higher in groups under restricted
fructose access as compared to Control (Figure 4(A), P <
0.01) with higher levels in F12L as compared to F12D
(Figure 4(A), P < 0.01). GTT showed impaired glucose
tolerance in F24 and F12L groups as compared to control
(Figure 4(B), P < 0.01).
There were no significant changes in insulin levels among
groups (Table 1). Triglyceride levels were lower in restricted
fructose access groups (Table 1, P < 0.01). Both plasma
cholesterol and urinary corticosterone levels showed no
diﬀerence among the groups (Table 1).
Light/dark diﬀerences in BP were present in Control, F24,
and F12D groups (Figure 5(A), P < 0.05). The circadian
BP rhythm was not seen in the F12L (Figure 5(A)). Fructose
consumption produced an increase in BP in the F24 group
during the dark phase when compared to the Control group
during the same phase (Figure 5(A), P < 0.05) and also
when compared to F24 during the light phase (Figure 5(A),
P < 0.05). This fructose eﬀect was not observed in the F12D
group (Figure 5(A)). All groups showed elevated HR during

the dark as compared to the light phase (Figure 5(B), P <
0.05) with no eﬀect of the fructose regimen (Figure 5(B)).

4. Discussion
The increase in fructose consumption, due to its widespread
presence in the modern diet, has become a major public
health concern. This is related to evidence that excessive
fructose intake may have detrimental eﬀects, including the
promotion of obesity and its cardiovascular and metabolic
complications [1, 2]. Studies focused on the direct eﬀects of
fructose intake in animals and humans showed increased BP,
dyslipidemia, insulin resistance, and glucose intolerance [3–
8]. In addition to the detrimental eﬀects of a high-fructose
diet, the timing of consumption might have additional
eﬀects. Changes in circadian feeding patterns, such as the
night eating syndrome (NES), can promote weight gain,
hormonal changes, and psychological disorders in either in
animals or humans [10–14, 24]. In this study, we evaluated
the time eﬀect (light or dark) of fructose consumption on BP,
body weight, and metabolic and hormonal parameters. We
observed that day or night restricted fructose consumption
increased body weight gain and glycemia. Further changes
were observed in mice submitted to light-restricted fructose
access: glucose intolerance, exacerbated hyperglycemia, and
a lack of circadian BP oscillation. These additional changes
were observed after 8 weeks of treatment, suggesting that
the chronic aspect of the restricted regimen itself might be
responsible, at least partially, for these results.
The circadian BP rhythm refers to the daily variation in
BP that in humans shows higher levels during day vs. night.
Healthy subjects usually present a 10–20% decline in arterial
BP during nighttime intervals which is called the “dipper”
pattern [25]. Impaired nocturnal BP decline (nondipping)
is a BP abnormality that is frequently seen among patients
with diabetes [26–30]. In order to follow the L/D BP rhythm
in our study, we used radiotelemetry for BP monitoring
in conscious, undisturbed mice. 24 hr BP recordings showed,
as expected, that control mice exhibited light/dark circadian
oscillations with lower BP seen during the light period, the
inactive period for mice [4, 31–33]. When fructose access
was restricted to the light phase (F12L), the light/dark BP
rhythm was nonexistent. This could be related, at least partly,
to the drinking pattern since the F12L group also showed a
lack of circadian oscillation in fluid intake, that is, similar
levels during the light and dark periods. This indicates that
animals spent more time, during the light phase, drinking
and therefore awake and possibly active. Blood pressure
circadian rhythm disruption may also be due to changes in
sleep since it has been observed in diabetic patients, who
wake up more frequently during the night (for instance,
due to nocturia) [34]. Although sleep disruption may also
be associated with stress [35], stress as documented by unchanged urinary corticosterone does not seem to be responsible for the observed cardiovascular and metabolic eﬀects.
Therefore, the disturbance in circadian BP pattern in the
F12L group might be due to the timing of fructose ingestion
(during the light phase) itself. Possibly, a higher fructose load
or longer treatment could produce a shift in the BP circadian
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Figure 3: 12 h fluid intake in control and fructose groups. ANOVA showed main eﬀect of fructose diet [F (3.20) = 8.4, P < 0.001], light/dark
(F (1.20) = 50.2, P < 0.00001) and interaction between diet and light/dark (F (3.20) = 5.7, P < 0.01). § P < 0.01 light vs. dark. ∗ P < 0.01
versus Control.
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Figure 4: (A) Fasting glycemia in control and fructose groups. F12L and F12D mice showed hyperglicemia ANOVA treatment (F (1.18)
= 12.3, P < 0.0003). ∗ P < 0.01 versus control. (B) Glucose tolerance test estimated by area under the time curve (AUC) in control and
fructose-treated groups. F24 h and F12L mice showed impaired glucose tolerance. ANOVA treatment (F (1.16) = 4.9, P < 0.05). ∗ P < 0.01
versus Control.

pattern in the F12L. However, these speculations do not
aﬀect the conclusion drawn from this group: fructose access
restricted to the light phase produces disruption in BP
rhythms.
The circadian pattern on HR light/dark oscillations,
showing a rhythmic pattern of variation in HR during 24
hours characterized by higher HR in the dark (awake period)
over the light period (sleep period), was not aﬀected by any
of the treatments. As previously shown by our group [4, 22],
although nocturnal BP was increased in F24 when compared
to controls, no further changes due to fructose were observed
in HR.
Circadian changes, such as the nondipping BP pattern,
are associated with diabetic micro- and macrovascular [36–
41] complications and end-organ damage [42]. The circadian changes in BP and fluid intake observed in F12L could

also be implicated in the impaired glucose metabolism (exacerbated hyperglycemia and glucose intolerance), exclusively
observed in this group (F12L). Preliminary information suggests derangements in renal histology in mice with fructose
access restricted to the light phase (Morris et al., unpublished
data). Changes in circadian pattern of food consumption
can lead to weight gain, metabolic dysfunction [10–14, 43],
and increased risk of obesity and diabetes [44] in humans.
The light phase-restricted fructose drinking regimen could
be a parallel for human NES, which is associated with hyperglycemia, glucose intolerance [45], and weight gain without
changes in total caloric consumption [12, 46], similar to our
observations in mice. Although the mechanism behind lightfed weight gain in mice is unknown, the study of Arble et
al., showed that there is causal evidence that feeding at the
“wrong” time can lead to weight gain [10].
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Figure 5: MAP (A) and HR (B) were recorded for 24 h and analyzed during 24 h light and dark phases. ANOVA showed main eﬀect of
light/dark for MAP (F (1.32) = 11.2, P < 0.005) and HR (F (1.32) = 16.62, P < 0.0003). § P < 0.05 light versus dark. ∗ P < 0.05 versus
Control.

Although F12L mice showed greater impairment in
glucose handling, both groups on restricted fructose access
(F12L and F12D) showed increased BW gain and hyperglycemia, not observed in the F24 group. Chronic misalignments between endogenous circadian timing system and
behavioral cycles have adverse metabolic eﬀects in humans
[43], including increased risk of obesity and diabetes [44]. As
shown by our group [4, 6], 24 h access to fructose produces
glucose intolerance without increases in BW. Therefore, the
circadian restriction aspect of the drinking regimen itself
could contribute to the increase in weight gain and blood
glucose levels observed in F12L and F12D.
A high-fructose diet in rodents has been associated with
cardiovascular dysregulation and insulin resistance [4, 6, 47–
49], More specifically, increased fructose intake, in both, animals and humans, increases blood pressure and causes
dyslipidemia and changes in glucose handling [3–8]. As

expected, mice receiving fructose 24 h a day exhibited nocturnal hypertension [4, 6]. However, BP was not increased in
groups on restricted fructose access (F12L and F12D) despite
the circadian disruption observed in the F12L group. Diet
concentration and length of treatment are important factors
for hypertension development in the rodent fructose model
[50]. Therefore, the restricted aspect of the fructose access
regimen itself could be a possible explanation for the absence
of BP increase in the F12L and F12D groups.
As mentioned previously, fructose consumption is often
associated with dyslipidemia. Chronic consumption of fructose led to hypercholesterolemia without changes in plasma
triglycerides [4, 6, 51, 52]. However, in this study, the F24
group showed no changes in cholesterol. This could be
due to the nature of the fructose source, since in previous
studies [4, 6] fructose was given in the chow (pellet diet
containing 67% carbohydrate—98% fructose, 13% fat, and

6
20% protein) instead of as a fluid (10% fructose solution).
Both groups on restricted access (F12L and F12D) had lower
levels of triglycerides with no changes in cholesterol. Since
circulating factors such as glucose and triglycerides can be
modulated by time-restricted food intake access [13, 53], the
restricted nature of the fructose drinking regimen itself could
explain the results observed in these groups.

5. Conclusion
In conclusion, we demonstrated that circadian phase restriction of fructose access leads to changes in glucose homeostasis, body weight gain, and light/dark BP rhythms. The
data suggests that even moderate circadian changes might
contribute to the onset or development of the metabolic
syndrome symptoms, which might be exacerbated by the
timing of fructose consumption. The results have clinical
implications since time of day and intake may be considered
in the overall treatment regimen.
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